Cette molécule est présentement en essai clinique pour la leucémie myéloïde aigüe et pour les syndromes myéloprolifératifs chroniques JAK2.
Voir
__________________________________
http://en.wikipedia.org/wiki/Lestaurtinib
_____________________________________
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
http://bloodjournal.hematologylibrary.o ... 11/12/5663
-------------------
In this issue of Blood, Hexner and colleagues report that lestaurtinib (CEP701), an orally applicable small molecular inhibitor of FLT3, also targets JAK2 and holds promise as a candidate drug for the treatment of patients with myeloproliferative disorders (MPDs).
http://bloodjournal.hematologylibrary.o ... 11/12/5419
_________________________________
CEP-701 (Lestaurtinib) in Myelofibrosis
This study is currently recruiting participants.
Verified by Myeloproliferative Disorders-Research Consortium, April 2008
http://clinicaltrials.gov/ct2/show/NCT00668421
__________________________________________
Do You Know JAK? (Etude de cas)
http://www.hematology.org/education/tra ... es/JAK.cfm
___________________________________
